research use only
Cat.No.S7783
| Related Targets | Akt Wnt/beta-catenin HSP PKC ROCK Integrin Bcr-Abl Actin FAK Kinesin |
|---|---|
| Other Microtubule Associated Inhibitors | Nocodazole MMAF Patupilone (Epothilone B) Lexibulin (CYT997) CW069 ABT-751 (E7010) Epothilone A Cucurbitacin B TAI-1 Vindoline |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| SKMEL-5 | Growth inhibition assay | Cytotoxic concentration required to inhibit 50% cell growth in SKMEL-5 melanoma cell lines, ED50=3.00E-08 μM | ||||
| A-549 | Growth inhibition assay | Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines, ED50=1.20E-06 μM | ||||
| MCF-7 | Growth inhibition assay | Cytotoxic concentration required to inhibit 50% cell growth in MCF-7 breast carcinoma cell lines, ED50=3.80E-06 μM | ||||
| HT-29 | Growth inhibition assay | Cytotoxic concentration required to inhibit 50% cell growth in HT-29 colon adenocarcinoma cell lines, ED50=1.20E-06 μM | ||||
| MLM melanoma cell | Growth inhibition assay | Cytotoxic concentration required to inhibit 50% cell growth in MLM melanoma cell lines, ED50=1.40E-06 μM | ||||
| M14 | Cytotoxicity assay | In vitro cytotoxic activity was tested against human melanoma cancer (M14) cell line, GI50=0.0001 μM | ||||
| SK-OV3 | Cytotoxicity assay | In vitro cytotoxic activity tested against human ovarian cancer (SK-OV3) cell line, GI50=0.0001 μM | ||||
| HL60 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human HL60 cells after 72 hrs by MTT assay, IC50=0.0001 μM | |||
| SK-OV-3 | Growth inhibition assay | 48 h | Growth inhibition of human SK-OV-3 after 48 hrs by SRB assay, GI50=0.00013 μM | |||
| HepG2 cells | Cytotoxicity assay | Cytotoxicity against human HepG2 cells, IC50=0.00014 μM | ||||
| ZR-75-1 | Cytotoxicity assay | Cytotoxicity against ZR-75-1 cell line, IC50=0.00024 μM | ||||
| HeLa cell | Cytotoxicity assay | Cytotoxicity against HeLa cell line, IC50=0.0003 μM | ||||
| HCT116 cell | Cytotoxicity assay | Cytotoxicity against HCT116 cell line, IC50=0.00035 μM | ||||
| KBV1 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay, IC50=0.0004 μM | |||
| SKOV3 | Cytotoxicity assay | Cytotoxicity against human SKOV3 cells by SRB assay, GI50=0.00042 μM | ||||
| SKOV3 cells | Growth inhibition assay | Growth inhibition of human SKOV3 cells by sulforhodamine B assay, GI50=0.00042 μM | ||||
| HeLa cells | Cytotoxicity assay | Cytotoxicity against human HeLa cells by MTT assay, IC50=0.00051 μM | ||||
| DU145 cells | Cytotoxicity assay | Cytotoxicity against human DU145 cells by SRB assay, GI50=0.00054 μM | ||||
| DU145 cells | Growth inhibition assay | Growth inhibition of human DU145 cells by sulforhodamine B assay, GI50=0.00054 μM | ||||
| SK-N-BE | Proliferation assay | 72 h | Antiproliferative activity in human SK-N-BE cells assessed as cell viability after 72 hrs by MTT assay, IC50=0.00058 μM | |||
| NCIH460 cells | Cytotoxicity assay | 48 h | Cytotoxicity against human NCIH460 cells after 48 hrs by SRB assay, GI50=0.0006 μM | |||
| KB-VIN10 cells | Proliferation assay | 72 h | Antiproliferative activity against human KB-VIN10 cells over-expressing P-gp 170/MDR1 after 72 hrs by methylene blue assay, IC50=0.0007 μM | |||
| HCT116 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human HCT116 cells assessed as reduction of [3H]thymidine incorporation after 72 hrs by scintillation counting, IC50=0.00074 μM | |||
| DU145 cells | Cytotoxicity assay | 48 h | Cytotoxicity against human DU145 cells after 48 hrs by SRB assay, GI50=0.0008 μM | |||
| RS4:11 cells | Proliferation assay | 72 h | Antiproliferative activity against human RS4:11 cells after 72 hrs by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test, IC50=0.0008 μM | |||
| HCT 116 | Growth inhibition assay | Concentration which produces 50% inhibition of growth of human colon tumor HCT 116, IC50=0.0009 μM | ||||
| HeLa cells | Cytotoxicity assay | 72 h | Cytotoxicity against human HeLa cells after 72 hrs by resazurin based fluorescence assay, IC50=0.0009 μM | |||
| BNL 1ME A.7R.1 cells | Cytotoxicity assay | Cytotoxicity against mouse BNL 1ME A.7R.1 cells, IC50=0.0009 μM | ||||
| Calu6 | Proliferation assay | 48 h | Antiproliferative activity against human Calu6 after 48 hrs by spectrophotometry, IC50=0.00094 μM | |||
| melanoma B16 cell | Growth inhibition assay | Concentration which produces 50% inhibition of growth of murine melanoma B16 cell line, IC50=0.001 μM | ||||
| DU145 cells | Cytotoxicity assay | Cytotoxicity against human DU145 cells by SRB assay, GI50=0.001 μM | ||||
| HCT116 cells | Proliferation assay | 72 h | Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay, IC50=0.001 μM | |||
| HCT15 cells | Proliferation assay | 72 h | Antiproliferative activity against human HCT15 cells after 72 hrs by MTS assay, IC50=0.001 μM | |||
| HL60 cells | Proliferation assay | 72 h | Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.001 μM | |||
| A10 cells | Growth inhibition assay | 48 h | Growth inhibition of rat A10 cells after 48 hrs by MTT assay, IC50=0.001 μM | |||
| HUVEC cells | Growth inhibition assay | 48 h | Growth inhibition of HUVEC cells after 48 hrs by MTT assay, IC50=0.001 μM | |||
| HL60 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human HL60 cells after 72 hrs by MTT assay, IC50=0.001 μM | |||
| HL60 cells | Proliferation assay | 72 h | Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.001 μM | |||
| NCI-H522 cells | Growth inhibition assay | 48 h | Growth inhibition of human NCI-H522 cells after 48 hrs by SRB assay, GI50=0.001 μM | |||
| MDA-MB-435 cells | Growth inhibition assay | 48 h | Growth inhibition of human MDA-MB-435 cells after 48 hrs by SRB assay, GI50=0.001 μM | |||
| OVCAR3 | Growth inhibition assay | 48 h | Growth inhibition of human OVCAR3 cells after 48 hrs by SRB assay, GI50=0.001 μM | |||
| NCI/ADR-RES cells | Growth inhibition assay | 48 h | Growth inhibition of human NCI/ADR-RES cells after 48 hrs by SRB assay, GI50=0.001 μM | |||
| PC3 cells | Growth inhibition assay | 48 h | Growth inhibition of human PC3 cells after 48 hrs by SRB assay, GI50=0.001 μM | |||
| DU145 cells | Growth inhibition assay | 48 h | Growth inhibition of human DU145 cells after 48 hrs by SRB assay, GI50=0.001 μM | |||
| MDA-MB-231 cells | Growth inhibition assay | 48 h | Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay, GI50=0.001 μM | |||
| CEM cells | Cytotoxicity assay | 72 h | Cytotoxicity against human CEM cells after 72 hrs by MTT assay, IC50=0.001 μM | |||
| HCT116 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay, IC50=0.001 μM | |||
| MDA-MB-435 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay, IC50=0.001 μM | |||
| HaCaT cells | Proliferation assay | Antiproliferative activity against human HaCaT cells assessed as cell viability by MTT assay, IC50=0.001 μM | ||||
| HL60 cells | Proliferation assay | 72 h | Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay, IC50=0.001 μM | |||
| HL60 cells | Proliferation assay | 72 h | Antiproliferative activity against human HL60 cells after 72 hrs by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test, IC50=0.001 μM | |||
| HT-29 | Growth inhibition assay | Growth inhibition of human HT-29 cells by MTT assay, IC50=0.001 μM | ||||
| HL60 cells | Proliferation assay | 72 h | Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay, IC50=0.001 μM | |||
| Hs578T cells | Growth inhibition assay | 48 h | Growth inhibition of human Hs578T cells after 48 hrs by SRB assay, GI50=0.001 μM | |||
| HL60 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human HL60 cells after 72 hrs by MTT assay, IC50=0.001 μM | |||
| SKOV3 cells | Growth inhibition assay | Growth inhibition of human SKOV3 cells by MTT assay, IC50=0.001 μM | ||||
| MDA-MB-468 cells | Cytotoxicity assay | 4 days | Cytotoxicity against human MDA-MB-468 cells assessed as cell viability after 4 days by MTS assay, IC50=0.0011 μM | |||
| MCF7 cells | Proliferation assay | 72 h | Antiproliferative activity in human MCF7 cells assessed as cell viability after 72 hrs by MTT assay, IC50=0.00111 μM | |||
| H460 | Cytotoxicity assay | Cytotoxicity against human H460 cells by sulforhodamine B test, IC50=0.0012 μM | ||||
| H460 | Proliferation assay | Antiproliferative activity against human H460 cells, IC50=0.00124 μM | ||||
| NCI-H460 cells | Cytotoxicity assay | 72 h | Cytotoxic activity against human NCI-H460 cells after 72 hrs by sulforhodamine B test, IC50=0.0013 μM | |||
| OVCAR8 cells | Growth inhibition assay | 96 h | Growth inhibition of human OVCAR8 cells overexpressing P-glycoprotein after 96 hrs, IC50=0.0013 μM | |||
| NCI/ADR-RES cells | Cytotoxicity assay | Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition by trypan blue exclusion assay, IC50=0.0013 μM | ||||
| OVCAR8 cells | Cytotoxicity assay | 96 h | Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy, IC50=0.0013 μM | |||
| NCI/ADR-RES cells | Cytotoxicity assay | 96 h | Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy, IC50=0.0013 μM | |||
| OVCAR8 cells | Cytotoxicity assay | Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by trypan blue exclusion assay, IC50=0.0013 μM | ||||
| HuTu 80 cells | Proliferation assay | 72 h | Antiproliferative activity in human HuTu 80 cells assessed as cell viability after 72 hrs by MTT assay, IC50=0.00137 μM | |||
| K562 cells | Cytotoxicity assay | Cytotoxicity against human K562 cells, IC50=0.0014 μM | ||||
| NCI/ADR (MDR) cells | Function assay | Cell cycle arrest in NCI/ADR (MDR) cells by accumulation at G2/M phase, IC50=0.0015 μM | ||||
| HUVEC | Proliferation assay | Antiproliferative activity against human HUVEC, IC50=0.0015 μM | ||||
| KB cell | Proliferation assay | Antiproliferative activity against human KB cell line by methylene blue dye assay, IC50=0.0015 μM | ||||
| KB-VIN10 cell | Proliferation assay | Antiproliferative activity against human KB-VIN10 cell line by methylene blue dye assay, IC50=0.0015 μM | ||||
| Human SH-SY5Y neuroblastoma cells | Function assay | Inhibitory concentration against Human SH-SY5Y neuroblastoma cells, IC50=0.0015 μM | ||||
| SW620 cells | Proliferation assay | 72 h | Antiproliferative activity in human SW620 cells assessed as cell viability after 72 hrs by MTT assay, IC50=0.00152 μM | |||
| Molt4/C8 cells | Proliferation assay | Antiproliferative activity against human Molt4/C8 cells, IC50=0.0016 μM | ||||
| ACHN cell | Proliferation assay | Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay, IC50=0.0016 μM | ||||
| Molt4/C8 cells | Proliferation assay | 3 days | Antiproliferative effect against human Molt4/C8 cells after 3 days, IC50=0.0016 μM | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 63 mg/mL
(199.14 mM)
Ethanol : 34 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 316.35 | Formula | C18H20O5 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 117048-59-6 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | COC1=C(C=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)O | ||
| Targets/IC50/Ki |
β-tubulin
0.4 μM(Kd)
|
|---|---|
| In vitro |
Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively. 1 μM of this compound inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. This chemical demonstrates great relative binding capacity, reaching 78% of colchicine binding.
|
| Kinase Assay |
Competitive binding assay using LC-MS/MS
|
|
Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of this compound are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
|
|
| In vivo |
In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry. This compound (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
How to make solution for in vivo IP injection of it?
Answer:
We've tested some vehicles for this compound, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve it in DMSO clearly first. Then add PEG, after they mixed well, then dilute with water.